Passage Bio stock holds near the 52-week low

Passage Bio stock (ISIN US70267E1055) traded at USD 4.75 on September 17, 2026, with a market capitalization of USD 15.28 million and volume of 1.57K shares, according to Robinhood data for PASG.

Price sits near the floor

The same data set showed a session range of USD 4.75 to USD 4.98 on September 17, 2026, leaving the stock 4.6 percent below the day's high and at the low of the day. Over the past year, the shares have ranged from USD 3.29 to USD 20.00, a gap that keeps the current quote near the lower end of the 52-week band.

Recent quarter remains the reference

Passage Bio reported a net loss of USD 22.4 million in the second quarter of 2026, according to its quarterly update. The company also ended the quarter with USD 21.2 million in cash and cash equivalents, while research and development expense stood at USD 12.7 million.

Those figures matter because Passage Bio is still a development-stage biotech, so the cash balance and quarterly burn rate frame how long the company can keep advancing its pipeline before it needs more funding. The USD 22.4 million loss in Q2 2026 also gives investors a concrete comparison point against the USD 12.7 million R&D spend in the same period.

Liquidity is the focus

For investors, the key question is whether the current USD 15.28 million market value already reflects the limited cash runway implied by the Q2 2026 figures. The share price on September 17, 2026 stayed close to the 52-week low, underscoring how tightly the market is pricing that risk.

More news and analyses on Passage Bio stock